SELLAS Life Sciences Group Q1 2026 Earnings Report

SELLAS Life Sciences Group EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.06
• Beat/Miss: N/A
• One Year Ago EPS: N/A

SELLAS Life Sciences Group Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

SELLAS Life Sciences Group Announcement Details

• Quarter: Q1 2026
• Date: 5/12/2026
• Time: Before Market Opens
• Conference Call Date: Monday, May 11, 2026
• Conference Call Time: 4:00PM ET

SELLAS Life Sciences Group (NASDAQ:SLS) is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1. GPS is currently being evaluated in ongoing Phase II/III clinical trials for acute myeloid leukemia (AML), malignant pleural mesothelioma and ovarian cancer. SELLAS is also exploring combination regimens of GPS with immune checkpoint inhibitors to enhance antitumor activity, as well as next-generation cellular approaches intended to broaden its therapeutic platform beyond peptide vaccines.

SELLAS conducts its clinical trials across multiple geographies, including North America, Europe and Japan, leveraging collaborations with leading academic research centers and contract research organizations. These partnerships enable the company to advance its programs efficiently through regulatory pathways and to access patient populations in key oncology indications.

The management team at SELLAS brings together seasoned executives and scientific leaders with extensive experience in oncology drug development. The company remains committed to translating its WT1-targeted immunotherapy approach into new treatment options for patients with high-unmet-need cancers.